# Sino Biopharmaceutical (Chia Tai Tianqing)

Source: https://onco.cc/companies/sino-biopharm/  
OnCo record `sino-biopharm` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sino Biopharm, through Chia Tai Tianqing, sells anlotinib, one of China's biggest cancer drugs, and acquired LaNova Medicines to add bispecific antibodies and ADCs.

## Summary

Anlotinib (Focus V) approved 2018 across lung cancer, sarcoma and thyroid cancer; the PD-L1 antibody benmelstobart (TQB2450) approved 2024 for small cell lung cancer with anlotinib; a large hepatitis and oncology generics franchise. In 2025 it agreed to acquire LaNova Medicines, whose PD-1 x VEGF bispecific LM-299 had been licensed to Merck & Co. in 2024, for up to about $951 million, an example of Chinese pharma buying Chinese biotech.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Also known as: Sino Biopharm; 中国生物制药; Chia Tai Tianqing; CTTQ; Chia Tai Tianqing Pharmaceutical; Nanjing Shunxin Pharmaceutical; Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical
- Tags: china
- HQ: Hong Kong / Nanjing
- Type: pharma
- Website: https://www.sinobiopharm.com
- Ticker: 1177.HK

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Sino_Biopharmaceutical_Limited
- Official website (archived copy): https://web.archive.org/web/20251122085435/https://www.sinobiopharm.com/en/

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [AL2846](https://onco.cc/drugs/al2846/), [Anlotinib](https://onco.cc/drugs/anlotinib/), [Benmelstobart](https://onco.cc/drugs/benmelstobart/), [LM-108](https://onco.cc/drugs/lm-108/), [LM-302](https://onco.cc/drugs/lm-302/), [TQ-B3234](https://onco.cc/drugs/tq-b3234/), [TQB2102](https://onco.cc/drugs/tqb2102/), [TQB2450](https://onco.cc/drugs/tqb2450/), [TQB2825](https://onco.cc/drugs/tqb2825/), [TQB2868](https://onco.cc/drugs/tqb2868/), [TQB2922](https://onco.cc/drugs/tqb2922/), [TQB2930](https://onco.cc/drugs/tqb2930/), [TQB3454](https://onco.cc/drugs/tqb3454/), [TQB3616](https://onco.cc/drugs/tqb3616/), [TQB3702](https://onco.cc/drugs/tqb3702/), [TQB3909](https://onco.cc/drugs/tqb3909/), [TQB6411](https://onco.cc/drugs/tqb6411/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)
- trials: [A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer](https://onco.cc/trials/nct07043725/), [A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer](https://onco.cc/trials/nct07003074/), [A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients](https://onco.cc/trials/nct06469879/), [A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer](https://onco.cc/trials/nct05913089/), [A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma](https://onco.cc/trials/nct05987358/), [A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)](https://onco.cc/trials/nct06962267/), [A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxal](https://onco.cc/trials/nct07483684/), [A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma](https://onco.cc/trials/nct06566586/), [A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advan](https://onco.cc/trials/nct07653685/), [A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality](https://onco.cc/trials/nct06496490/), [A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer](https://onco.cc/trials/nct06561607/), [A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies](https://onco.cc/trials/nct07011186/), [A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection](https://onco.cc/trials/nct07367529/), [A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC](https://onco.cc/trials/nct07815223/), [A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma](https://onco.cc/trials/nct06860971/), [A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Can](https://onco.cc/trials/nct04854668/), [A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer](https://onco.cc/trials/nct07538271/), [A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer](https://onco.cc/trials/nct06198751/), [A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer](https://onco.cc/trials/nct06431490/), [A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer](https://onco.cc/trials/nct04523272/), [A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer](https://onco.cc/trials/nct06202261/), [ALTER 0303](https://onco.cc/trials/alter-0303/), [Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.](https://onco.cc/trials/nct05862337/), [Clinical Studies for the Treatment of Advanced Solid Tumors](https://onco.cc/trials/nct06825494/), [Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors](https://onco.cc/trials/nct07512583/), [Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C](https://onco.cc/trials/nct06821503/), [Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms](https://onco.cc/trials/nct06767813/), [Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer](https://onco.cc/trials/nct05780567/), [Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma](https://onco.cc/trials/nct07385703/), [Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer](https://onco.cc/trials/nct07367516/), [Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer](https://onco.cc/trials/nct07008976/), [Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma](https://onco.cc/trials/nct06829771/), [Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma](https://onco.cc/trials/nct06854445/), [Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma](https://onco.cc/trials/nct07548177/), [D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standar](https://onco.cc/trials/nct06300177/), [Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis](https://onco.cc/trials/nct07545213/), [Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas](https://onco.cc/trials/nct07407803/), [Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer](https://onco.cc/trials/nct06702618/), [Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC](https://onco.cc/trials/nct07294261/), [Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (A](https://onco.cc/trials/nct04846634/), [Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)](https://onco.cc/trials/nct07501169/), [SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05576480/), [The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer](https://onco.cc/trials/nct06452706/), [To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer](https://onco.cc/trials/nct05365178/), [TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer](https://onco.cc/trials/nct07044908/), [TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer](https://onco.cc/trials/nct07047365/), [Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC](https://onco.cc/trials/nct06456138/)

---
JSON: https://onco.cc/api/v1/entities/sino-biopharm.json